Breaking News

Elan, Boehringer in Antibody Pact

Collaboration will leverage BI's technical development, mfg. expertise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan and Boehringer Ingelheim have entered into a global technical development and manufacturing agreement for antibody-based therapeutics. BI will perform technical development, clinical manufacturing and all related regulatory filing support services for antibodies discovered by Elan. Elan will lead the discovery science, preclinical activities, clinical development and commercialization of such antibodies. Dr Johannes Roebers, senior vice president and head of Biologic Strategy, Planning a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters